#USA #New York #Securities Fraud #Pomerantz #EyePoint

EyePoint, Inc. Under Investigation by Pomerantz Law Firm

In a significant development for investors of EyePoint, Inc. (NASDAQ: EYPT), the Pomerantz Law Firm has initiated an investigation concerning claims related to potential securities fraud and other unlawful practices by the company and certain officers or directors. This inquiry has been prompted by alarming disclosures that have dramatically impacted the stock's value.

The Clinical Trial Setbacks

On August 17, 2026, EyePoint published a press release announcing topline results from their pivotal Phase 3 clinical trial known as LUGANO. This trial was crucial for evaluating DURAVYU™, an innovative treatment for wet age-related macular degeneration (wet AMD). However, the results revealed disappointing outcomes regarding the primary efficacy endpoint—specifically, the comparison of best corrected visual acuity (BCVA) against the market-leading Eylea (aflibercept) produced by Regeneron Pharmaceuticals. This failure was significant, leading to a staggering drop in EyePoint’s stock price, which plummeted by nearly 67%, closing at $4.87 per share.

The situation worsened when, on October 19, 2026, EyePoint disclosed additional disappointing results from another pivotal clinical trial, LUCIA. This trial further assessed DURAVYU’s effectiveness but ended with similar unfavorable conclusions, as it did not demonstrate statistical non-inferiority to the existing standard treatment, Eylea. Following this second blow, the company's stock price continued its downward spiral, nosediving by more than 85% to close at just $0.44 per share.

The Legal Implications

In light of these revelations, investors of EyePoint are advised to reach out to Pomerantz LLP to learn more about their rights and possible avenues for recourse. The law firm is known for tackling matters that involve corporate fraud and fiduciary breaches, boasting a strong history of recovering damages for investors. Danielle Peyton, a representative of Pomerantz, invites investors to make contact via email at [email protected] or by phone at 646-581-9980, ext. 7980.

Overview of Pomerantz Law Firm

Pomerantz LLP has long been recognized as a leading firm in corporate, securities, and antitrust class litigation. Founded by Abraham L. Pomerantz—an influential figure revered as the dean of the class action bar—the firm has gained commendable trust in the realm of securities class actions over the last 85 years. Pomerantz continues its mission, advocating for victims of securities fraud and championing corporate accountability.

The firm’s rigorous approach involves thorough investigation and legal strategy designed to address the intricate dynamics of corporate behavior, ensuring that investors' interests are prioritized. As EyePoint's situation unfolds, it stands as a crucial reminder of the risks inherent in volatile market segments such as biopharmaceuticals, which can be significantly impacted by clinical outcomes and regulatory scrutiny.

Conclusion

The potential ramifications for EyePoint shareholders are profound given the drastic movements in the stock's value following these trial announcements. As the Pomerantz Law Firm investigates, investors are encouraged to stay informed, understand their legal rights, and consider their next steps carefully. This case not only highlights the importance of transparent corporate practices but also reaffirms the critical role of legal oversight in protecting investor rights in the financial landscape.